JP2002523036A5 - - Google Patents

Download PDF

Info

Publication number
JP2002523036A5
JP2002523036A5 JP2000566305A JP2000566305A JP2002523036A5 JP 2002523036 A5 JP2002523036 A5 JP 2002523036A5 JP 2000566305 A JP2000566305 A JP 2000566305A JP 2000566305 A JP2000566305 A JP 2000566305A JP 2002523036 A5 JP2002523036 A5 JP 2002523036A5
Authority
JP
Japan
Prior art keywords
fusion protein
target protein
protein
region
homodimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000566305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002523036A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/019329 external-priority patent/WO2000011033A2/en
Publication of JP2002523036A publication Critical patent/JP2002523036A/ja
Publication of JP2002523036A5 publication Critical patent/JP2002523036A5/ja
Pending legal-status Critical Current

Links

JP2000566305A 1998-08-25 1999-08-25 イムノフュージンとしての新脈管形成インヒビターの発現および輸送 Pending JP2002523036A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9788398P 1998-08-25 1998-08-25
US60/097,883 1998-08-25
PCT/US1999/019329 WO2000011033A2 (en) 1998-08-25 1999-08-25 Expression and export of angiostatin and endostatin as immunofusins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009196091A Division JP2009273478A (ja) 1998-08-25 2009-08-26 イムノフュージンとしての新脈管形成インヒビターの発現および輸送

Publications (2)

Publication Number Publication Date
JP2002523036A JP2002523036A (ja) 2002-07-30
JP2002523036A5 true JP2002523036A5 (cg-RX-API-DMAC7.html) 2006-10-19

Family

ID=22265602

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000566305A Pending JP2002523036A (ja) 1998-08-25 1999-08-25 イムノフュージンとしての新脈管形成インヒビターの発現および輸送
JP2009196091A Pending JP2009273478A (ja) 1998-08-25 2009-08-26 イムノフュージンとしての新脈管形成インヒビターの発現および輸送
JP2013041498A Pending JP2013128490A (ja) 1998-08-25 2013-03-04 イムノフュージンとしての新脈管形成インヒビターの発現および輸送

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009196091A Pending JP2009273478A (ja) 1998-08-25 2009-08-26 イムノフュージンとしての新脈管形成インヒビターの発現および輸送
JP2013041498A Pending JP2013128490A (ja) 1998-08-25 2013-03-04 イムノフュージンとしての新脈管形成インヒビターの発現および輸送

Country Status (20)

Country Link
US (3) US20030139365A1 (cg-RX-API-DMAC7.html)
EP (1) EP1107989B1 (cg-RX-API-DMAC7.html)
JP (3) JP2002523036A (cg-RX-API-DMAC7.html)
CN (2) CN101386651A (cg-RX-API-DMAC7.html)
AT (1) ATE462725T1 (cg-RX-API-DMAC7.html)
AU (1) AU761027B2 (cg-RX-API-DMAC7.html)
BR (1) BR9913331A (cg-RX-API-DMAC7.html)
CA (1) CA2339331C (cg-RX-API-DMAC7.html)
CZ (1) CZ302303B6 (cg-RX-API-DMAC7.html)
DE (1) DE69942207D1 (cg-RX-API-DMAC7.html)
DK (1) DK1107989T3 (cg-RX-API-DMAC7.html)
ES (1) ES2342239T3 (cg-RX-API-DMAC7.html)
HK (1) HK1042503A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0103329A3 (cg-RX-API-DMAC7.html)
NO (1) NO20010918L (cg-RX-API-DMAC7.html)
PL (1) PL202057B1 (cg-RX-API-DMAC7.html)
PT (1) PT1107989E (cg-RX-API-DMAC7.html)
RU (1) RU2240328C2 (cg-RX-API-DMAC7.html)
WO (1) WO2000011033A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200101290B (cg-RX-API-DMAC7.html)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999016889A1 (en) * 1997-10-01 1999-04-08 G.D. Searle & Co. Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
CN1318092C (zh) * 1998-04-15 2007-05-30 利思进药品公司 含有抗体-细胞因子融合蛋白和血管生成抑制剂的免疫治疗用组合物
JP2002523036A (ja) * 1998-08-25 2002-07-30 レキシジェン ファーマシューティカルズ コーポレイション イムノフュージンとしての新脈管形成インヒビターの発現および輸送
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001010912A1 (en) 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
IL131803A0 (en) * 1999-09-08 2001-03-19 Genena Ltd Method for improving the efficiency of cancer gene therapy
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
CZ2003214A3 (cs) 2000-06-29 2003-08-13 Merck Patent Gmbh Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
JP2003000268A (ja) * 2000-08-25 2003-01-07 Pfizer Prod Inc 血管新生にかかわる疾患を診断および治療するための方法および組成物
EP1197550A3 (en) * 2000-08-25 2002-11-20 Pfizer Products Inc. Methods and compositions for diagnosing and treating disorders involving angiogenesis
US7160858B2 (en) 2000-09-01 2007-01-09 Philadelphia, Health And Education Corporation Methods and compositions for inhibiting angiogenesis
EP1313504B1 (en) * 2000-09-01 2006-11-29 Philadelphia, Health and Education Corporation Methods and compositions for inhibiting angiogenesis
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
BR0209177A (pt) 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
WO2003093303A1 (en) 2002-05-06 2003-11-13 Board Of Regents, The University Of Texas System Targeting proteins to deliver therapeutic or diagnostic reagents
ATE471946T1 (de) * 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
JP2007525972A (ja) * 2003-08-29 2007-09-13 チルドレンズ メディカル センター コーポレーション エンドスタチンのn末端からの抗血管新生性ペプチド
US7524811B2 (en) 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
KR101163424B1 (ko) 2003-12-30 2012-07-13 메르크 파텐트 게엠베하 Il-7 융합 단백질
EP1699821B1 (en) 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
CA2552590A1 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
CA2553883C (en) * 2004-01-22 2013-04-02 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-cancer antibodies with reduced complement fixation
JP2005301419A (ja) * 2004-04-07 2005-10-27 Hitachi Ltd ディスクアレイ装置およびそのデータ処理方法
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
ES2325344B1 (es) * 2004-11-02 2010-06-09 Univ Madrid Autonoma Inhibidores de angiogenesis multifuncionales y multivalentes.
CN101072793B (zh) 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
RU2303997C2 (ru) * 2005-09-27 2007-08-10 Автономная некоммерческая организация Научно-технический центр "Фармбиопресс" Конъюгат, обладающий избирательным действием по отношению к раковым опухолям
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
WO2007045465A1 (en) * 2005-10-21 2007-04-26 F. Hoffmann-La Roche Ag Method for the recombinant expression of a polypeptide
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
SI1966238T1 (sl) * 2005-12-30 2012-08-31 Merck Patent Gmbh Variante interlevkina-12P40 z izboljšano stabilnostjo
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Fc와 인간 아포리포단백질(a)크링글절편의 융합단백질 LK8­Fc
US7981446B2 (en) * 2007-11-26 2011-07-19 Forhumantech. Co., Ltd. Pharmaceutical compositions and methods for delivering nucleic acids into cells
AT506216B1 (de) 2008-02-13 2009-07-15 Peter Dr Hernuss Zusammensetzung zur aufnahme über mukoses gewebe
RU2372354C1 (ru) * 2008-02-28 2009-11-10 Сергей Викторович Луценко Слитый белок, имеющий активность ингибитора ангиогенеза
CA2754408A1 (en) * 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
AU2010238858A1 (en) 2009-04-22 2011-12-08 Merck Patent Gmbh Antibody fusion proteins with modified FcRn binding sites
KR101579318B1 (ko) * 2010-04-29 2015-12-21 엘지전자 주식회사 태양 전지 및 그 제조 방법
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
RU2465283C1 (ru) * 2011-06-27 2012-10-27 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвити Рекомбинантный гибридный полипептид, способный ингибировать пролиферацию эндотелиальных клеток человека in vitro, и способ его получения
EP2561888A1 (en) * 2011-08-23 2013-02-27 Deutsches Krebsforschungszentrum Protein comprising NC-1 for treating angiogenesis-related diseases
EP2999017B1 (en) * 2013-06-14 2019-11-06 LG Chem, Ltd. Organic photovoltaic cell
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US20160126391A1 (en) * 2014-10-31 2016-05-05 Byd Company Limited Solar cell module and manufacturing method thereof
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
CA3002588C (en) * 2015-10-23 2021-11-23 Apogenix Ag Single-chain cd137-receptor agonist proteins
CN108473549A (zh) * 2015-10-23 2018-08-31 阿珀吉科吉尼科斯股份公司 单链gitr受体激动剂蛋白
EP3364995B1 (en) * 2015-10-23 2021-08-04 Apogenix AG Single-chain cd27-receptor agonist proteins
JP7051697B2 (ja) 2015-12-03 2022-04-11 ハイデルベルク バイオテック ゲーエムベーハー 線維症又は線維症関連疾患を治療及び診断するための手段及び方法
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN109824779B (zh) * 2017-11-23 2023-05-26 中山大学 一种包含IgG的Fc结构域和EB病毒包膜糖蛋白胞外域的融合蛋白
US11845784B2 (en) 2018-04-17 2023-12-19 Heidelberg Biotech Gmbh Means and methods for the treatment of angiogenesis-, fibrosis- and cancer-related diseases with protein oligomers comprising NC-1-Fc
WO2020056152A1 (en) * 2018-09-12 2020-03-19 Chang Liu Single chain constructs
US20240100134A1 (en) * 2021-01-20 2024-03-28 Monash University Fusion proteins
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
CA3255646A1 (en) * 2022-03-09 2023-09-14 Immunofyx N-TERMINAL FC CONJUGATED CANCER IMMUNOTHERAPY AGENTS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05271294A (ja) * 1992-01-24 1993-10-19 Japan Found Cancer Res ヒトプロヒビチンおよびそれをコードするdna
US5643783A (en) * 1993-12-01 1997-07-01 President And Fellows Of Harvard College Collagen and uses therefor
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5922852A (en) * 1995-06-07 1999-07-13 Oklahoma Medical Research Foundation 3' untranslated region of the human prohibitin gene
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
EP0857210B1 (en) * 1995-10-23 2003-09-03 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
CN1318092C (zh) * 1998-04-15 2007-05-30 利思进药品公司 含有抗体-细胞因子融合蛋白和血管生成抑制剂的免疫治疗用组合物
HK1038881A1 (zh) * 1998-04-17 2002-04-04 利思进药品公司 通过共同给予前列腺素抑制剂增强抗体-细胞因子融合蛋白介导的免疫应答
CA2331370A1 (en) * 1998-06-03 1999-12-09 The Children's Medical Center Corporation Protein oligomer compositions comprising endostatin protein and methods of using the same
JP2002523036A (ja) * 1998-08-25 2002-07-30 レキシジェン ファーマシューティカルズ コーポレイション イムノフュージンとしての新脈管形成インヒビターの発現および輸送
US7524811B2 (en) * 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin

Similar Documents

Publication Publication Date Title
RU2001105917A (ru) Гомодимерный слитый белок, имеющий активность ингибитора ангиогенеза (варианты), молекула днк, кодирующая гомодимерный слитый белок, вектор для экспрессии гомодимерного слитого белка, способ трансфекции клетки млекопитающего и способ получения гомодимерного слитого белка
US6653450B1 (en) Mutated recombinant collagens
JP2025028857A5 (cg-RX-API-DMAC7.html)
Berdichevsky et al. Matrix-assisted refolding of single-chain Fv–cellulose binding domain fusion proteins
KR970002915B1 (ko) 제ⅷ인자 활성을 가지는 신규한 단백질 : 유전공학-제조 세포를 사용하는 그의 제조방법 및 그것을 함유하는 의약 조성물
AU605291B2 (en) Process for the purification of recombinant polypeptides
CN108794639B (zh) 一种重组纤连蛋白及其应用
US6207420B1 (en) Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in Escherichia coli
JP2003530070A5 (cg-RX-API-DMAC7.html)
CN110511280B (zh) 一种透皮重组纤连蛋白及其应用
CA2339331A1 (en) Expression and export of angiogenesis inhibitors as immunofusins
CA2339889A1 (en) Identification of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
CA2289912A1 (en) Human receptor proteins; related reagents and methods
RU2001130984A (ru) Экспрессия и экспорт белков интерферона-альфа в виде слитых белков, содержащих Fc-фрагмент иммуноглобулина
CA2273196A1 (en) Isolated mammalian monocyte cell genes; related reagents
WO2000049159A1 (en) Collagen-binding physiologically active polypeptide
CA2295189A1 (en) Type-1 ribosome-inactivating protein
CN116554309A (zh) 一种重组人源ⅲ型胶原蛋白及其制备方法和应用
KR870001311A (ko) 단백질 및 폴리펩티드의 제조 방법
CN118006523A (zh) A型肉毒素的重组基因工程菌及其制备和应用
US20020102709A1 (en) Collagen-binding physiologically active polypeptide
CN119462899B (zh) 一种高活性重组人源xvii型胶原蛋白及其制备方法和应用
EP0234592A1 (en) Plasmid containing DNA fragment coding for human immunoglobulin G Fc region protein and use thereof for production of said protein
RU2336279C2 (ru) БЕЛОК IFNAB-BPI, ЕГО ПРЕДШЕСТВЕННИК, МОЛЕКУЛА ДНК, ЭКСПРЕССИРУЮЩИЙ ВЕКТОР, СПОСОБ ПРОДУЦИРОВАНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ IFN-α ИЛИ IFN-β
CN111808881A (zh) 一种高效表达afp3-pten融合蛋白的方法